Angiogenesis Antibodies

Cat. No.

A34892

CAS No.

3030730-59-4

Vasigrobart

Synonyms: REGN-13335

Vasigrobart is a human IgG1 antibody specifically targeting platelet-derived growth factor subunit B (PDGFB). With a molecular weight of approximately 145 kDa, this CHO-expressed antibody is designed for applications involving PDGFB-mediated signaling pathways. It is suitable for research in cellular growth, differentiation, and associated pathological conditions. For isotype control experiments, Human IgG4 kappa can be utilized as a reference.

Cat. No.

AT0006

CAS No.

2923284-73-3

Tovecimig

Tovecimig is a G1-scFv-based monoclonal antibody that specifically targets both vascular endothelial growth factor A (VEGFA) and Delta-like ligand 4 (DLL4), two key regulators of angiogenesis. By simultaneously inhibiting VEGFA and DLL4 signaling, Tovecimig offers a dual anti-angiogenic mechanism that may support research into tumor vascularization, resistance to anti-VEGF therapies, and other angiogenesis-dependent pathologies.

Cat. No.

AT0012

CAS No.

1253180-81-2

Radretumab

Radretumab is a CHO-expressed humanized IgG1κ monoclonal antibody targeting the extradomain B (ED-B) of fibronectin, an isoform selectively expressed in tumor neovasculature. Radretumab is designed for tumor-targeted delivery and is widely used in cancer research to study angiogenesis, extracellular matrix remodeling, and antibody-directed therapeutic strategies. Recommended isotype control: Human IgG1 kappa isotype control.

Cat. No.

AT0069

Anti-VEGFB Antibody (CSL346)

Synonyms: CSL346

Anti-VEGFB Antibody (CSL346) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets vascular endothelial growth factor B (VEGFB), playing a crucial role in angiogenesis and vascular development. This antibody is comprised of a human IgG4SP heavy chain and a human kappa light chain, resulting in a total molecular weight of approximately 145 kDa. For experimental control purposes, Human IgG4 kappa, Isotype Control is recommended. This antibody is suitable for a range of research applications, providing a valuable tool for studies focused on vascular biology and associated pathological conditions.

Cat. No.

AT0074

Anti-DLL4 Antibody

Cat. No.

AT0203

CAS No.

1791420-09-1

Dilpacimab

Synonyms: ABT165; PR1283233

Dilpacimab (ABT165) is a dual-variable domain immunoglobulin engineered for high potency, simultaneously targeting the delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) pathways. This bifunctional antibody is designed to inhibit two critical signaling pathways involved in angiogenesis and tumor growth, making it a valuable tool for cancer research. Dilpacimab is suitable for use in various experimental settings to explore the role of these pathways in oncogenesis and potential therapeutic interventions.

Cat. No.

AT0232

Anti-VEGFR2/KDR/CD309 Antibody

The Anti-VEGFR2/KDR/CD309 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), also known as Kinase Insert Domain Receptor (KDR) or CD309. This antibody comprises a murine IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 150 kDa. For accurate experimental controls, it is recommended to use the Human IgG1 kappa, Isotype Control, which is designed to match the isotype of this antibody. This product is essential for research in angiogenesis, vascular biology, and oncology, providing a valuable tool for both therapeutic and diagnostic development.

Cat. No.

AT0234

Anti-NOTCH1 Antibody

The Anti-NOTCH1 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the NOTCH1 protein. This antibody is composed of a human IgG2 heavy chain and a human lambda light chain, and exhibits a predicted molecular weight of 150 kDa. For isotype control purposes, Human IgG2 kappa, Isotype Control is recommended. This product is ideal for use in various immunological assays to study the role of NOTCH1 in cellular differentiation, proliferation, and apoptotic processes.

Cat. No.

AT0297

CAS No.

1359940-55-8

Tarextumab

Synonyms: OMP 59R5; Anti-Human NOTCH2 Recombinant Antibody

Tarextumab (OMP-59R5) is a fully human IgG2 monoclonal antibody designed to target and inhibit Notch2 and Notch3 receptors. This antibody exhibits potent anti-tumor activity by interfering with the Notch signaling pathway, which is often implicated in the regulation of cell differentiation, proliferation, and apoptosis. Tarextumab is primarily utilized in oncological research to explore therapeutic strategies against various cancers where Notch signaling plays a critical role.

Cat. No.

AT0359

CAS No.

1607793-29-2

Faricimab

Synonyms: RG7716

Faricimab is a bispecific antibody that simultaneously targets Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), exhibiting a favorable safety and tolerability profile. This therapeutic agent is designed to inhibit retinal vascular leakage, cell death, and inflammation, which are critical pathological factors in retinal ischemia/reperfusion (I/R) injury and subretinal choroidal neovascularization (sCNV) in mouse models. Clinical studies have shown that Faricimab offers statistically significant improvements in visual acuity compared to Ranibizumab. It is indicated for the treatment of various retinal diseases, including wet age-related macular degeneration (w-AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), making it a valuable tool in ophthalmic research and therapeutic applications.

Cat. No.

AT0376

CAS No.

2415205-37-5

Zansecimab

Synonyms: LY-3127804

Zansecimab (LY-3127804) is a monoclonal antibody of the immunoglobulin G4-kappa subclass, specifically targeting angiopoietin 2 (Ang 2). This antibody is designed for potential use in studies focused on angiogenesis and immune regulation, providing a valuable tool for research in these critical areas of biological and medical science.

Cat. No.

AT0434

CAS No.

2428381-49-9

Pulocimab

Pulocimab is a monoclonal antibody targeting VEGFR2 (vascular endothelial growth factor receptor 2), designed for use in cancer research. This antibody binds specifically to VEGFR2, inhibiting its signaling pathways, which are critical for tumor angiogenesis and growth. Pulocimab offers a valuable tool for researchers studying the molecular mechanisms of cancer progression and exploring potential therapeutic strategies targeting angiogenesis.

Cat. No.

AT0443

CAS No.

1268714-50-6

Carotuximab

Synonyms: TRC105; DE-122

Carotuximab (TRC105) is an IgG1 monoclonal antibody designed to inhibit endoglin (CD105), a critical component of the Smad signaling pathway. This antibody exhibits both immunomodulatory and antineoplastic properties, making it a valuable tool in cancer research and therapy development. Carotuximab targets endoglin-expressing cells, thereby interfering with cellular processes essential for tumor growth and angiogenesis.

Cat. No.

AT0467

CAS No.

1638338-43-8

Navicixizumab

Synonyms: OMP-305B83; Anti-DLL4 Reference Antibody (navicixizumab

Navicixizumab (OMP-305B83) is a bispecific antibody designed to inhibit both vascular endothelial growth factor (VEGF) and Delta-like ligand 4 (DLL4). This dual inhibition mechanism makes it a potent candidate for use in oncology research, particularly in studies involving ovarian, primary peritoneal, or fallopian tube cancers. Navicixizumab has shown potential for use in combination with Paclitaxel, enhancing its applicability in therapeutic research protocols aimed at targeting cancer angiogenesis and tumor growth.

Cat. No.

AT0500

CAS No.

1024603-93-7

Olaratumab

Synonyms: IMC-3G3; LY3012207

Olaratumab (IMC-3G3; LY3012207) is a human monoclonal IgG1 antibody targeting the platelet-derived growth factor receptor alpha (PDGFRα). This antibody exhibits potent antitumor activity by inhibiting the PDGFRα pathway, which is implicated in various forms of cancer cell proliferation and tumor growth. Olaratumab is utilized primarily in research focused on the development and therapeutic intervention of malignancies where PDGFRα plays a critical role.

Cat. No.

AT0601

CAS No.

1415642-51-1

MEDI-3617

MEDI-3617 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Angiopoietin-2 (Ang2/ANGPT2). This antibody is comprised of a human IgG2 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For isotype control, it is recommended to use Human IgG2 kappa, Isotype Control. MEDI-3617 is designed for precise binding and neutralization of Ang2, making it highly relevant for research into vascular development and angiogenic processes.

Cat. No.

AT0604

CAS No.

1243262-17-0

Demcizumab

Synonyms: OMP 21M18

Demcizumab (OMP 21M18) is a monoclonal antibody targeting DLL4, a critical regulator in the Notch signaling pathway. This antibody acts as a potent inhibitor of the Notch pathway, which plays a significant role in cell differentiation, proliferation, and apoptosis. The inhibition of this pathway by Demcizumab has demonstrated efficacy in various cancer models, both as a standalone treatment and in combination with chemotherapy. This makes it a valuable tool for research in cancer biology, particularly in studies exploring the role of Notch signaling in tumorigenesis and therapeutic resistance.

Cat. No.

AT0609

CAS No.

934216-54-3

Alacizumab

Alacizumab is a humanized monoclonal antibody expressed in Chinese Hamster Ovary (CHO) cells, specifically designed to target VEGFR2/KDR/CD309. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, resulting in a predicted molecular weight of 144.08 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended. Alacizumab is applicable in research focused on angiogenesis and vascular biology due to its specificity in binding to VEGFR2/KDR/CD309, a critical receptor in vascular endothelial growth factor (VEGF) signaling pathways.

Cat. No.

AT0658

Anti-NOTCH3 Antibody

Cat. No.

AT0660

VGX-100

VGX-100 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target vascular endothelial growth factor C (VEGFC). This antibody is comprised of human immunoglobulin G1 (huIgG1) heavy chains and human lambda (huλ) light chains, exhibiting a predicted molecular weight of 143.6 kDa. For isotype control experiments, Human IgG1 kappa, Isotype Control is recommended. VGX-100 is applicable in research focusing on the modulation of angiogenesis and lymphangiogenesis, pertinent to studies in cancer and vascular biology.

Cat. No.

AT0717

CAS No.

2517939-46-5

Zifibancimig

Synonyms: RO-7250284

Zifibancimig is a monoclonal antibody of the IgG1κ isotype, designed to target and neutralize both VEGFA (Vascular Endothelial Growth Factor A) and ANGPT2 (Angiopoietin-2). This dual specificity makes it a valuable tool for investigating the complex interplay between these two critical angiogenic factors in various pathological conditions. Zifibancimig is utilized primarily in research focused on angiogenesis, tumor growth, and vascular diseases.

Cat. No.

AT0784

CAS No.

2250342-36-8

Vulinacimab

Synonyms: HLX-06

Vulinacimab (HLX-06) is a monoclonal antibody targeting VEGFR-2, a receptor overexpressed in various tumor types. This antibody is instrumental in studying the mechanisms of angiogenesis and the associated processes of proliferation, survival, migration, and differentiation of endothelial cells in cancer research. Vulinacimab provides a valuable tool for investigating the role of VEGFR-2 in oncological pathologies and therapeutic interventions.

Cat. No.

AT0793

CAS No.

347396-82-1

Ranibizumab (anti-VEGF)

Synonyms: RG-6321 (anti-VEGF

Ranibizumab (RG-6321), a humanized monoclonal antibody fragment, targets and inhibits vascular endothelial growth factor A (VEGF-A), recognizing all its isoforms including VEGF110, VEGF121, and VEGF165. This anti-VEGF agent is effective in slowing vision loss in vivo and is primarily utilized in research focused on wet age-related macular degeneration (AMD).

Cat. No.

AT0817

CAS No.

2997627-68-4

Inlecitug

Inlecitug is a chimeric monoclonal antibody designed to target the human kinase insert domain receptor (KDR). By specifically binding to KDR, Inlecitug effectively blocks the interaction between vascular endothelial growth factor (VEGF) and KDR, subsequently inhibiting angiogenesis. This inhibition plays a crucial role in exerting antitumor activity, making Inlecitug a valuable tool for cancer research.

Cat. No.

AT0840

CAS No.

1438851-35-4

ABP 215

ABP 215 (Bevacizumab-awwb), a biosimilar to Bevacizumab, is a humanized IgG1 monoclonal antibody that specifically targets vascular endothelial growth factor A (VEGFA), thereby inhibiting its interaction with VEGF receptors. This antibody demonstrates anticancer properties by impeding angiogenesis, a critical process in tumor growth and metastasis. ABP 215 is utilized in research focused on metastatic colorectal cancer (mCRC), providing a valuable tool for investigating disease mechanisms and potential therapeutic interventions.